vy1706
·Code: VY1706
vy1706: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Voyager Therapeutics, Inc. (VYGR) | Preclinical |
FDA Decisions
FDA_MeetingThe FDA cleared the Investigational New Drug (IND) application for VY1706, an investigational tau silencing gene therapy for Alzheimer's disease.(VYGR)
Frequently asked questions
Who is developing vy1706?
vy1706 is being developed by Voyager Therapeutics, Inc..
What is vy1706's latest FDA decision?
The most recent tracked FDA decision for vy1706 is FDA_Meeting for The FDA cleared the Investigational New Drug (IND) application for VY1706, an investigational tau silencing gene therapy for Alzheimer's disease..
Get deeper analysis on vy1706
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis